Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.

Orlando, Ambrogio; Renna, Sara; Mocciaro, Filippo; Cappello, Maria; Di Mitri, Roberto; Randazzo, Claudia; Cottone, Mario

Orlando, Ambrogio; Renna, Sara; Mocciaro, Filippo; Cappello, Maria; Di Mitri, Roberto; Randazzo, Claudia; Cottone, Mario.

Affiliation

Orlando A; DI.BI.MIS., Division of Internal Medicine Villa Sofia-V. Cervello Hospital, University of Palermo, Palermo, Italy. ambrogiorlando@gmail.com

Inflamm Bowel Dis ; 18(5): 826-31, 2012 May.

Article in En | MEDLINE | ID: mdl-21837774

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Crohn Disease/drug therapy; Glucocorticoids/therapeutic use; Secondary Prevention; Adalimumab; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Secondary Prevention / Antibodies, Monoclonal, Humanized / Glucocorticoids / Anti-Inflammatory Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Inflamm Bowel Dis Journal subject: GASTROENTEROLOGIA Year: 2012 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google